Viral vectors carry genetic material into cells by exploiting the molecular mechanisms by which viruses transmit their genomes to other cells for infection.It can occur in vivo or in vitro.Plasmid carriers are plasmids artificially constructed on the basis of natural plasmids to adapt to laboratory operations.In recent years, global viral vector and plasmid DNA manufacturing has developed rapidly, with a compound growth rate of about 28% during 2018-2018.In 2018, global sales of viral vector and plasmid DNA production reached $381 million.In 2018, China accounted for about 4% of global sales.In the next five years, the production of viral vectors and plasmid DNA products in China will continue to grow rapidly.Viral vector and plasmid DNA manufacturing are mainly divided into viral vector manufacturing and plasmid DNA manufacturing, among which viral vector manufacturing accounts for the largest proportion, accounting for nearly 38% of the total market in 2018.Viral vector and plasmid DNA manufacturing is mainly used for drug development and production of cancer, genetic diseases, viral infections and other diseases, among which cancer is the main application field, accounting for 35% in 2018.The market is highly competitive.Brammer Bio, Oxford BioMedica, Cobra Biologics, FinVector and Lonza are major suppliers.They have mastered key technologies and patents, and they have a fixed customer base. They have established a monopoly in the market.Gene therapy technology innovation and clinical trials have mushroomed in recent years, and a number of gene therapy projects have been approved for marketing in the United States, the European Union, China and other countries.The target of gene therapy has also been gradually expanded from single gene genetic diseases to malignant tumors, infectious diseases, cardiovascular diseases, autoimmune diseases, metabolic diseases and other major diseases.
Highlights
The global Viral Vector and Plasmid DNA market was valued at US$ 807.3 million in 2022 and is anticipated to reach US$ 2327.4 million by 2029, witnessing a CAGR of 19.3% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global Viral Vector and Plasmid DNA key players include BioReliance, Oxford BioMedica, UniQure, Cobra Biologics, etc. Global top four manufacturers hold a share over 45%.
North America is the largest market, with a share about 50%, followed by Europe, and Asia-Pacific, both have a share over 40 percent.
In terms of product, Viral Vectors is the largest segment, with a share about 80%. And in terms of application, the largest application is Cancers, followed by Inherited Disorders, Viral Infections, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Viral Vector and Plasmid DNA, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vector and Plasmid DNA.
The Viral Vector and Plasmid DNA market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Viral Vector and Plasmid DNA market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Viral Vector and Plasmid DNA companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Brammer Bio
Oxford BioMedica
Cobra Biologics
FinVector
Lonza
BioReliance
MolMed
FUJIFILM Diosynth Biotechnologies
UniQure
Aldevron
Richter-Helm
Eurogentec
OBiO Technology
Yposkesi
Cell and Gene Therapy Catapult
MassBiologics
Biovian
VGXI
Gene Synthesis
PlasmidFactory
Jikai Gene
Segment by Type
Plasmid DNA
Viral Vector
Segment by Application
Cancer
Virus Infection
Hereditary Disease
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Viral Vector and Plasmid DNA companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Viral Vector and Plasmid DNA Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Plasmid DNA
1.2.3 Viral Vector
1.3 Market by Application
1.3.1 Global Viral Vector and Plasmid DNA Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Cancer
1.3.3 Virus Infection
1.3.4 Hereditary Disease
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Viral Vector and Plasmid DNA Market Perspective (2018-2029)
2.2 Viral Vector and Plasmid DNA Growth Trends by Region
2.2.1 Global Viral Vector and Plasmid DNA Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Viral Vector and Plasmid DNA Historic Market Size by Region (2018-2023)
2.2.3 Viral Vector and Plasmid DNA Forecasted Market Size by Region (2024-2029)
2.3 Viral Vector and Plasmid DNA Market Dynamics
2.3.1 Viral Vector and Plasmid DNA Industry Trends
2.3.2 Viral Vector and Plasmid DNA Market Drivers
2.3.3 Viral Vector and Plasmid DNA Market Challenges
2.3.4 Viral Vector and Plasmid DNA Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Viral Vector and Plasmid DNA Players by Revenue
3.1.1 Global Top Viral Vector and Plasmid DNA Players by Revenue (2018-2023)
3.1.2 Global Viral Vector and Plasmid DNA Revenue Market Share by Players (2018-2023)
3.2 Global Viral Vector and Plasmid DNA Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Viral Vector and Plasmid DNA Revenue
3.4 Global Viral Vector and Plasmid DNA Market Concentration Ratio
3.4.1 Global Viral Vector and Plasmid DNA Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Viral Vector and Plasmid DNA Revenue in 2022
3.5 Viral Vector and Plasmid DNA Key Players Head office and Area Served
3.6 Key Players Viral Vector and Plasmid DNA Product Solution and Service
3.7 Date of Enter into Viral Vector and Plasmid DNA Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Viral Vector and Plasmid DNA Breakdown Data by Type
4.1 Global Viral Vector and Plasmid DNA Historic Market Size by Type (2018-2023)
4.2 Global Viral Vector and Plasmid DNA Forecasted Market Size by Type (2024-2029)
5 Viral Vector and Plasmid DNA Breakdown Data by Application
5.1 Global Viral Vector and Plasmid DNA Historic Market Size by Application (2018-2023)
5.2 Global Viral Vector and Plasmid DNA Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Viral Vector and Plasmid DNA Market Size (2018-2029)
6.2 North America Viral Vector and Plasmid DNA Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Viral Vector and Plasmid DNA Market Size by Country (2018-2023)
6.4 North America Viral Vector and Plasmid DNA Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Viral Vector and Plasmid DNA Market Size (2018-2029)
7.2 Europe Viral Vector and Plasmid DNA Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Viral Vector and Plasmid DNA Market Size by Country (2018-2023)
7.4 Europe Viral Vector and Plasmid DNA Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Viral Vector and Plasmid DNA Market Size (2018-2029)
8.2 Asia-Pacific Viral Vector and Plasmid DNA Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Viral Vector and Plasmid DNA Market Size by Region (2018-2023)
8.4 Asia-Pacific Viral Vector and Plasmid DNA Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Viral Vector and Plasmid DNA Market Size (2018-2029)
9.2 Latin America Viral Vector and Plasmid DNA Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Viral Vector and Plasmid DNA Market Size by Country (2018-2023)
9.4 Latin America Viral Vector and Plasmid DNA Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Viral Vector and Plasmid DNA Market Size (2018-2029)
10.2 Middle East & Africa Viral Vector and Plasmid DNA Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Viral Vector and Plasmid DNA Market Size by Country (2018-2023)
10.4 Middle East & Africa Viral Vector and Plasmid DNA Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Brammer Bio
11.1.1 Brammer Bio Company Detail
11.1.2 Brammer Bio Business Overview
11.1.3 Brammer Bio Viral Vector and Plasmid DNA Introduction
11.1.4 Brammer Bio Revenue in Viral Vector and Plasmid DNA Business (2018-2023)
11.1.5 Brammer Bio Recent Development
11.2 Oxford BioMedica
11.2.1 Oxford BioMedica Company Detail
11.2.2 Oxford BioMedica Business Overview
11.2.3 Oxford BioMedica Viral Vector and Plasmid DNA Introduction
11.2.4 Oxford BioMedica Revenue in Viral Vector and Plasmid DNA Business (2018-2023)
11.2.5 Oxford BioMedica Recent Development
11.3 Cobra Biologics
11.3.1 Cobra Biologics Company Detail
11.3.2 Cobra Biologics Business Overview
11.3.3 Cobra Biologics Viral Vector and Plasmid DNA Introduction
11.3.4 Cobra Biologics Revenue in Viral Vector and Plasmid DNA Business (2018-2023)
11.3.5 Cobra Biologics Recent Development
11.4 FinVector
11.4.1 FinVector Company Detail
11.4.2 FinVector Business Overview
11.4.3 FinVector Viral Vector and Plasmid DNA Introduction
11.4.4 FinVector Revenue in Viral Vector and Plasmid DNA Business (2018-2023)
11.4.5 FinVector Recent Development
11.5 Lonza
11.5.1 Lonza Company Detail
11.5.2 Lonza Business Overview
11.5.3 Lonza Viral Vector and Plasmid DNA Introduction
11.5.4 Lonza Revenue in Viral Vector and Plasmid DNA Business (2018-2023)
11.5.5 Lonza Recent Development
11.6 BioReliance
11.6.1 BioReliance Company Detail
11.6.2 BioReliance Business Overview
11.6.3 BioReliance Viral Vector and Plasmid DNA Introduction
11.6.4 BioReliance Revenue in Viral Vector and Plasmid DNA Business (2018-2023)
11.6.5 BioReliance Recent Development
11.7 MolMed
11.7.1 MolMed Company Detail
11.7.2 MolMed Business Overview
11.7.3 MolMed Viral Vector and Plasmid DNA Introduction
11.7.4 MolMed Revenue in Viral Vector and Plasmid DNA Business (2018-2023)
11.7.5 MolMed Recent Development
11.8 FUJIFILM Diosynth Biotechnologies
11.8.1 FUJIFILM Diosynth Biotechnologies Company Detail
11.8.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.8.3 FUJIFILM Diosynth Biotechnologies Viral Vector and Plasmid DNA Introduction
11.8.4 FUJIFILM Diosynth Biotechnologies Revenue in Viral Vector and Plasmid DNA Business (2018-2023)
11.8.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.9 UniQure
11.9.1 UniQure Company Detail
11.9.2 UniQure Business Overview
11.9.3 UniQure Viral Vector and Plasmid DNA Introduction
11.9.4 UniQure Revenue in Viral Vector and Plasmid DNA Business (2018-2023)
11.9.5 UniQure Recent Development
11.10 Aldevron
11.10.1 Aldevron Company Detail
11.10.2 Aldevron Business Overview
11.10.3 Aldevron Viral Vector and Plasmid DNA Introduction
11.10.4 Aldevron Revenue in Viral Vector and Plasmid DNA Business (2018-2023)
11.10.5 Aldevron Recent Development
11.11 Richter-Helm
11.11.1 Richter-Helm Company Detail
11.11.2 Richter-Helm Business Overview
11.11.3 Richter-Helm Viral Vector and Plasmid DNA Introduction
11.11.4 Richter-Helm Revenue in Viral Vector and Plasmid DNA Business (2018-2023)
11.11.5 Richter-Helm Recent Development
11.12 Eurogentec
11.12.1 Eurogentec Company Detail
11.12.2 Eurogentec Business Overview
11.12.3 Eurogentec Viral Vector and Plasmid DNA Introduction
11.12.4 Eurogentec Revenue in Viral Vector and Plasmid DNA Business (2018-2023)
11.12.5 Eurogentec Recent Development
11.13 OBiO Technology
11.13.1 OBiO Technology Company Detail
11.13.2 OBiO Technology Business Overview
11.13.3 OBiO Technology Viral Vector and Plasmid DNA Introduction
11.13.4 OBiO Technology Revenue in Viral Vector and Plasmid DNA Business (2018-2023)
11.13.5 OBiO Technology Recent Development
11.14 Yposkesi
11.14.1 Yposkesi Company Detail
11.14.2 Yposkesi Business Overview
11.14.3 Yposkesi Viral Vector and Plasmid DNA Introduction
11.14.4 Yposkesi Revenue in Viral Vector and Plasmid DNA Business (2018-2023)
11.14.5 Yposkesi Recent Development
11.15 Cell and Gene Therapy Catapult
11.15.1 Cell and Gene Therapy Catapult Company Detail
11.15.2 Cell and Gene Therapy Catapult Business Overview
11.15.3 Cell and Gene Therapy Catapult Viral Vector and Plasmid DNA Introduction
11.15.4 Cell and Gene Therapy Catapult Revenue in Viral Vector and Plasmid DNA Business (2018-2023)
11.15.5 Cell and Gene Therapy Catapult Recent Development
11.16 MassBiologics
11.16.1 MassBiologics Company Detail
11.16.2 MassBiologics Business Overview
11.16.3 MassBiologics Viral Vector and Plasmid DNA Introduction
11.16.4 MassBiologics Revenue in Viral Vector and Plasmid DNA Business (2018-2023)
11.16.5 MassBiologics Recent Development
11.17 Biovian
11.17.1 Biovian Company Detail
11.17.2 Biovian Business Overview
11.17.3 Biovian Viral Vector and Plasmid DNA Introduction
11.17.4 Biovian Revenue in Viral Vector and Plasmid DNA Business (2018-2023)
11.17.5 Biovian Recent Development
11.18 VGXI
11.18.1 VGXI Company Detail
11.18.2 VGXI Business Overview
11.18.3 VGXI Viral Vector and Plasmid DNA Introduction
11.18.4 VGXI Revenue in Viral Vector and Plasmid DNA Business (2018-2023)
11.18.5 VGXI Recent Development
11.19 Gene Synthesis
11.19.1 Gene Synthesis Company Detail
11.19.2 Gene Synthesis Business Overview
11.19.3 Gene Synthesis Viral Vector and Plasmid DNA Introduction
11.19.4 Gene Synthesis Revenue in Viral Vector and Plasmid DNA Business (2018-2023)
11.19.5 Gene Synthesis Recent Development
11.20 PlasmidFactory
11.20.1 PlasmidFactory Company Detail
11.20.2 PlasmidFactory Business Overview
11.20.3 PlasmidFactory Viral Vector and Plasmid DNA Introduction
11.20.4 PlasmidFactory Revenue in Viral Vector and Plasmid DNA Business (2018-2023)
11.20.5 PlasmidFactory Recent Development
11.21 Jikai Gene
11.21.1 Jikai Gene Company Detail
11.21.2 Jikai Gene Business Overview
11.21.3 Jikai Gene Viral Vector and Plasmid DNA Introduction
11.21.4 Jikai Gene Revenue in Viral Vector and Plasmid DNA Business (2018-2023)
11.21.5 Jikai Gene Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Brammer Bio
Oxford BioMedica
Cobra Biologics
FinVector
Lonza
BioReliance
MolMed
FUJIFILM Diosynth Biotechnologies
UniQure
Aldevron
Richter-Helm
Eurogentec
OBiO Technology
Yposkesi
Cell and Gene Therapy Catapult
MassBiologics
Biovian
VGXI
Gene Synthesis
PlasmidFactory
Jikai Gene
听
听
*If Applicable.
